An interventional study of Vitrification medium oocyte, warming medium oocyte and Rapid-i in Infertility, sponsored by Vitrolife. Completed at 2 sites in United States. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2014-03-24.
Sponsored by Vitrolife · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate safety and performance of Vitrolife´s new oocyte vitrification/warming media and the vitrification device Rapid-i™, when using vitrification as a cryopreservation method for human oocytes.
A multi-center prospective sibling oocyte vitrification trial where, in the first phase, half of the patients' oocytes will be vitrified and warmed (experimental group). The remaining oocytes will not be vitrified and will serve as the control group. In the second phase all of the patients' oocytes will be vitrified and the embryo transfer will be performed in a following cycle. This simulates the situation of a normal cryopreservation embryo transfer. The study population consists of 20 women who will undergo a fresh IVF cycle during the study period. The primary objective in the first phase is to assess survival, fertilization and embryo development after oocyte vitrification/warming with the new media. The results will be compared with results from sibling oocytes which have not been vitrified. Secondary objectives are to assess the clinical results such as implantation, miscarriage and pregnancy rate as well as delivery rate and neonatal outcome.
The primary objective in the second phase is to assess the delivery rate after oocyte vitrification/warming with the new media. Secondary objectives are to assess survival, fertilization, embryo development, utilization rate, pregnancy rate and neonatal outcome on the previously vitrified and warmed oocytes. The results will be compared with results from a control group of patients, treated at the same clinics within the same time period, using the same inclusion and exclusion criteria. All patients who undergo embryo transfer will have a serum beta-hCG test conducted 14 days after oocyte retrieval. If positive, repeat beta-hCG testing will be conducted 2-4 days later. If appropriate, a pregnancy ultrasound will be conducted between 6-8 weeks gestation (menstrual age) to record gestational sac(s) and fetal heart beat. The delivery outcome will also be recorded. For patients with an unsuccessful treatment, there will be a follow-up period of 6 months after study completion. From this follow-up, data from frozen cycles, i.e. from embryos after oocyte vitrification, can be evaluated as well.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 17 is below the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Vitrolife is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Vitrification medium oocyte, warming medium oocyte and Rapid-i
Device: Vitrification medium oocyte, warming medium oocyte and Rapid-i
Media and device for vitrification of human oocytes
Embryo development after oocyte vitrification/warming.
Embryo development, as number of good quality blastocysts, after oocyte vitrification and warming.
Time frame: 5 days after oocyte retrieval
Implantation rate of previously vitrified/warmed oocytes.
Number of embryos implanted. Expressed as a percentage of number transferred.
Time frame: 4 weeks after embryo transfer
Ongoing pregnancy rate
Number of ongoing pregnancies at 3months. Expressed as a percentage of patients undergoing embryo transfer.
Time frame: 3 months after embryo transfer
Live birth
Number of lives births results from embryos transferred.
Time frame: 9 months after embryo transfer
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vitrolife